Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.

 

Autophagy (self-eating) is a critical cell process that allows cells to degrade and cycle damaged cell components.  In this case, TEX264 is key to identifying and recycling DNA with a permanent chemical link to a protein.

Covalent attachment of proteins to DNA is a constant problem.  Unless cells can clear their DNA of attached proteins they would die, so we knew they could do this, we just didn’t know how.

 Kristijan Ramadan’s group has uncovered how cells handle one example of this, the formation of a permanent link between DNA and a protein called Topoisomerase 1 to give a Topoisomerase 1 -cleavage complex (Top1-ccs).  Topoisomerase 1 (Top-1) is usually involved in unwinding DNA strands so that they may be easily copied, but if Top-1 gets permanently linked to DNA copying would get stuck and the cell would suffer further DNA damage. 

Specialised DNA repair machinery composed of the p97 ATPase, SPRTN protease and an autophagy receptor TEX264, tackles the linked protein-DNA.   Inactivation of the p97-SPRTN-TEX264 complex leads to accumulation of Top1-ccs and genomic instability. Pathological accumulation of Top1-ccs is linked to neurodegeneration and cancer.

The discovery of TEX264 and role it plays in resolving problems associated with covalent linking of proteins to DNA is important for cancer therapy, as Topoisomerase 1 inhibitors are one of the commonly used chemotherapeutics and they kill cancer cells by accumulation of Top1-ccs. Kristijan Ramadan’s report could be vital in treating tumours which have become resistant to Topoisomerase 1 inhibitors.

 

The full publication can be read here

Similar stories

New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes

A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Machine Learning Enhances Detection of Multiple Cancer Types from Blood

Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test’s potential to transform early cancer detection and improve patient outcomes.

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

Subashan Vadibeler wins 2024 Lasker Essay Contest

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.